Anti-Migraine Retargeting

The Challenge

A small Life Sciences organization had an established product in the Oral CGRP market focused on acute treatment of migraines.

Fifteen months post launch, the brand received an additional indication for the preventative treatment of episodic migraines.

Ahead of launch for the acute indication, Propensity4 leveraged market research to understand the attitudes of the HCP population.
We then correlated attitudes and behaviors demonstrated in claims data to develop a scoring mechanism across the HCP universe and developed targeting for 585 reps to accelerate adoption in acute patients.
Ahead of the preventative launch, Propensity4 applied our scoring mechanism to identify previously non-targeted HCPs with preventative patients.
At launch, PROPENSITY4 issued new targeting for the existing and a new preventative indication sales team.

PROPENSITY4 was able to deliver a final targeting scheme in 8 weeks, marrying primary and secondary data to create an informed targeting approach.

The brand was able to deliver 4x the forecast across both indications in a highly genericized market.

For more case studies and insights from Propensity4, click below.

Jump to a slide with the slide dots.

Propensity4 helped a large Life Sciences organization to implement structural changes to combat LOE on their Patient Solutions Program.

PROPENSITY4 built a most probable forecast to understand the future market landscape for a mid-sized Life Sciences organization.

Delivering refined targeting lists within 8 weeks to facilitate infusion centers to be “Infusion Ready”, 12 months from launch.